Holen Sie sich die Stockscreener-App
16.16
7.16%
1.08
Vorhandelsmarkt:
16.26
0.10
+0.62%
Schlusskurs vom Vortag:
$15.08
Offen:
$15.38
24-Stunden-Volumen:
1.66M
Relative Volume:
0.90
Marktkapitalisierung:
$1.96B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-8.00
EPS:
-2.02
Netto-Cashflow:
$-33.45M
1W Leistung:
+4.66%
1M Leistung:
+15.10%
6M Leistung:
-3.23%
1J Leistung:
-61.34%
1-Tages-Spanne:
$15.20
$16.22
1-Wochen-Bereich:
$14.06
$16.63
52-Wochen-Spanne:
$12.95
$51.22
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Vergleichen Sie TXG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
16.16 | 1.96B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
223.04 | 36.21B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
74.02 | 12.79B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
55.52 | 10.37B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
104.74 | 9.08B | 1.15B | 96.70M | -161.99M | 1.09 |
|
TEM
Tempus Ai Inc
|
47.64 | 7.50B | 640.44M | -743.28M | -206.93M | -11.29 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
Weiss Ratings Reaffirms Sell (E+) Rating for 10x Genomics (NASDAQ:TXG) - MarketBeat
TXG (10x Genomics) Preferred Stock : $0.0 Mil (As of Sep. 2024) - GuruFocus.com
RNA Transcriptome Profiling Tests Market Expands at 14.5% CAGR, Surpassing US$ 37 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.
Avanza Fonder AB Takes Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
TXG (10x Genomics) Future Policy Benefits - GuruFocus.com
TXG (10x Genomics) EBIT per Share : $-1.47 (TTM As of Sep. 2024) - GuruFocus.com
TXG (10x Genomics) Shareholder Yield % : 0.44% (As of Sep. 2024) - GuruFocus.com
TXG (10x Genomics) Earnings Yield (Joel Greenblatt) % : -7.27% (As of Sep. 2024) - GuruFocus.com
10x Genomics (NASDAQ:TXG) Trading Down 4.9%What's Next? - MarketBeat
Assenagon Asset Management S.A. Makes New $26.31 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (FRA:1KJ) Days Sales Outstanding : 53.41 (As of Sep. 2024) - GuruFocus.com
Mirador Capital Partners LP Boosts Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
The Analyst Verdict: 10x Genomics In The Eyes Of 6 Experts - Benzinga
JPMorgan Chase & Co. Has $8.03 Million Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (NASDAQ:TXG) Shares Gap UpTime to Buy? - MarketBeat
Morgan Stanley Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results - The Malaysian Reserve
10x Genomics Q4 Revenue Hits $165M with Mixed Results: Services Surge 35% YoY Despite Overall Decline - StockTitan
Diversified Trust Co Invests $511,000 in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting - Kilgore News Herald
10x Genomics: Struggling Amid Operational Challenges (NASDAQ:TXG) - Seeking Alpha
Vizgen Loses Antitrust Claims Against 10x In Biotech IP Fight - Law360
10x Genomics (NASDAQ:TXG) Shares Up 11.6%Here's What Happened - MarketBeat
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - StreetInsider.com
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
10x Genomics to Present at J.P. Morgan Healthcare Conference Next Week - StockTitan
10x Genomics, Inc. (NASDAQ:TXG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Cathie Wood's ARK ETF adjusts, adds 10X Genomics, sells Rocket Lab - Investing.com
Geode Capital Management LLC Boosts Stock Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics wins permanent injunction against NanoString - MSN
10x Genomics secures injunction against Bruker By Investing.com - Investing.com Australia
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products - The Malaysian Reserve
10x’s $31 Million Verdict Stands and NanoString’s GeoMx Blocked - Bloomberg Law
U.S. District Court Awards 10x Genomics Permanent Injunction in - GuruFocus.com
10x Genomics secures injunction against Bruker - Investing.com India
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products – Company AnnouncementFT.com - Financial Times
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products (PR Newswire) - Aktiellt
10x Genomics (NASDAQ:TXG) Trading Up 4.3%Should You Buy? - MarketBeat
State Street Corp Increases Stock Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Goldman Sachs Maintains 10x Genomics Inc(TXG) Sell Recommendation - MSN
10X Genomics' SWOT analysis: genomics firm navigates challenges, eyes recovery - Investing.com
Insider Sellers Might Regret Selling 10x Genomics Shares at a Lower Price Than Current Market Value - Simply Wall St
Barclays PLC Has $13.61 Million Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10X Genomics' SWOT analysis: genomics firm's stock faces instrument demand headwinds - Investing.com
XTX Topco Ltd Purchases 31,844 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Reports Third Quarter 2024 Financial Results - The Eastern Progress Online
46,029 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by Weiss Asset Management LP - MarketBeat
Quantinno Capital Management LP Raises Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Charles Schwab Investment Management Inc. Has $14.71 Million Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (FRA:1KJ) Current Ratio : 4.90 (As of Sep. 2024) - GuruFocus.com
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
10 X Genomics Inc-Aktie (TXG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Nov 22 '24 |
Sale |
13.69 |
6,693 |
91,612 |
872,574 |
| Hindson Benjamin J. | See Remarks |
Nov 22 '24 |
Sale |
13.69 |
5,807 |
79,485 |
339,897 |
7.02%
1.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):